Literature DB >> 11324640

Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura.

A H Loof, H H van Vliet, M C Kappers-Klunne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11324640     DOI： 10.1046/j.1365-2141.2001.02622-5.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 2.  Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.

Authors:  Suresh G Shelat; Jihui Ai; X Long Zheng
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

3.  ADAMTS13 gene mutations in children with hemolytic uremic syndrome.

Authors:  Hyoung Soo Choi; Hae Il Cheong; Nam Keun Kim; Doyeun Oh; Hye Won Park
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

4.  Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.

Authors:  Chen Liu; Lei Zhao; Jingzhong Zhao; Qinzhu Xu; Ying Song; Hui Wang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

5.  ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism?

Authors:  M C Kappers-Klunne; J G van Asten; H H van Vliet
Journal:  Ann Hematol       Date:  2009-02-11       Impact factor: 3.673

6.  Deficiency of ADAMTS-13 in pediatric patients with severe sepsis and impact on in-hospital mortality.

Authors:  Farheen Karim; Salman Naseem Adil; Bushra Afaq; Anwar Ul Haq
Journal:  BMC Pediatr       Date:  2013-03-28       Impact factor: 2.125
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.